Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets

“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance, and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China,” says Zlatko Rihter, CEO of Mölnlycke.
The manufacturing site, spanning 10,000 m2, will be set up in accordance with Mölnlycke’s global standards and is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027. This strategic move will help future-proof Mölnlycke’s growth in China, laying the foundation for future capacity expansion and local job creation.
“This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions,” adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke.
The Changshu site strengthens Mölnlycke’s position in Asia and aligns with China’s growing demand for advanced, locally manufactured healthcare solutions.
For more information, please contact:

Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Gothenburg, Sweden. 12 November 2025. Mölnlycke Health Care, a global leader in MedTech, is the first company to donate a patent to SKF’s groundbreaking digital platform, The Patent Bay – taking bold action to harness collaboration and accelerate innovation in sustainable healthcare.
Gothenburg, Sweden, 15 October 2025 Mölnlycke® Health Care is proud to announce that its global headquarters have placed number one in Sweden, and top 20 globally, in the prestigious Leesman® Index, a benchmark survey measuring workplace experience across thousands of organisations worldwide.
Brunswick, Maine, USA and Gothenburg, Sweden. 23 September 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick, Maine. This milestone marks the beginning of a $135 million investment aimed at significantly increasing Mölnlycke’s manufacturing capacity in the United States.
Gothenburg, Sweden. 17 September 2025. A new narrative review published in the current issue of Journal of Patient Safety, titled ’Putting Patients at Risk: The Effect of Health Care Provider Burnout on Patient Care in the Operating Room’ reveals alarmingly high levels of burnout among healthcare workers in operating rooms (ORs) and warns of the serious implications for staff well-being, care quality and ultimately patient safety.
Gothenburg, Sweden. 21 August 2025. Mölnlycke®, a world-leading MedTech company, has once again been recognised as a global sustainability leader, earning the prestigious EcoVadis Platinum medal for the second year in a row.
A new peer-reviewed study published in the Journal of Hospital Infection underscores the critical role of double gloving and indicator systems in reducing the risk of undetected glove breaches during surgery.
Gothenburg, Sweden, 26 June 2025. Mölnlycke Health Care, a global leader in MedTech, today announces its largest investment to date: a €115 million expansion of its wound care manufacturing capacity in Brunswick, Maine, USA.
Stockholm/Gothenburg – 24 June, 2025. Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.